Back to top
more

Abeona Therapeutics (ABEO)

(Delayed Data from NSDQ)

$6.42 USD

6.42
194,982

+0.04 (0.63%)

Updated Nov 8, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump

by Zacks Equity Research

Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

Moving Average Crossover Alert: Abeona Therapeutics

by Zacks Equity Research

Abeona Therapeutics Inc. (ABEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Abeona Therapeutics (ABEO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -47.83% and 68.04%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Abeona Therapeutics (ABEO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -56.25% and -54.83%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options

    by Zacks Equity Research

    Abeona Therapeutics (ABEO) needs investors to pay close attention to the stock based on moves in the options market lately.

      Why Abeona Therapeutics (ABEO) Could Be Positioned for a Slump

      by Zacks Equity Research

      Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

        Abeona Therapeutics (ABEO) Surges: Stock Moves 7.2% Higher

        by Zacks Equity Research

        Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

          Are Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock?

          by Zacks Equity Research

          Surging implied volatility makes Abeona Therapeutics (ABEO) stock lucrative to the option traders.

            Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised)

            by Zacks Equity Research

            The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

              Here's Why These 3 Biotech Stocks Might Stop Rallying

              by Zacks Equity Research

              The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

                Abeona Therapeutics (ABEO) Surges: Stock Moves 22.9% Higher

                by Zacks Equity Research

                Abeona Therapeutics (ABEO) shares rose nearly 23% in the last trading session, amid huge volumes.

                  Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6%

                  by Zacks Equity Research

                  Abeona Therapeutics Inc. (ABEO) moved big last session, as the company saw its shares rise over 10% on the day.

                    Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 5.8%

                    by Zacks Equity Research

                    Abeona Therapeutics Inc.(ABEO) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

                      Abeona Therapeutics (ABEO): Strong Industry, Solid Earnings Estimate Revisions

                      by Zacks Equity Research

                      Abeona Therapeutics (ABEO) in the Medical-Biomedical/Genetics space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.